Is there a qualitative interaction between adjuvant trastuzumab and size of the primaty tumor in breast cancer?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00007570" target="_blank" >RIV/61989592:15110/08:00007570 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Is there a qualitative interaction between adjuvant trastuzumab and size of the primaty tumor in breast cancer?

Original language description

Benefit of adjuvant trastuzumab in breast cancer has been reported in four randomized trials of phase III, and these results are consistent in showing improvement in disease-free survival (DFS). Current evidence for homogeneity of this DFS benefit in subgroups of patients with the different size of the primary HER2-positive tumor treated according to the HERA trial is reviewed. It is evident that current published evidence is insufficient to rule out that there is a cohort of patients with HER2-positivedisease who do not achieve a reduction in the risk of recurrence by adjuvant treatment with trastuzumab after completion of previous adjuvant chemo- and radiotherapy. An alternative interpretation of results of the HERA trial currently available in twoprimary reports (1-year, and 2-year median follow- up, respectively) is discussed. The risk factors of central nervous system (CNS) metastases in breast cancer and problem of CNS metastases in HER2-positive tumors are briefly reviewed. A

Czech name

Je kvalitní vzájemné působení mezi adjuvantní indikací trastuzumabu a velikostí primární tumoru u karcinomu prsu?

Czech description

Diskutovány výsledky trastuzumabu v adjuvantní indikaci.

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2008

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

55

Issue of the periodical within the volume

5

Country of publishing house

SK - SLOVAKIA

Number of pages

406

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—